|
Quotes & Info
|
| PLX > SEC Filings for PLX > Form 8-K on 6-Dec-2012 | All Recent SEC Filings |
6-Dec-2012
Other Events
On December 6, 2012, Protalix BioTherapeutics, Inc. (the "Company") issued a press release announcing that it has entered into a Clinical Development Agreement with Pfizer Inc. under which the Company will continue to manage, administer and sponsor current, ongoing clinical trials relating to ELELYSOTM (taliglucerase alfa). A copy of the press release is filed as Exhibit 99.1.
|
|